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Purpose: Although warfarin is an effective oral anticoagu-
lation (OAC) drug to reduce the risk of thromboembolism in 
patients with non-valvular atrial fibrillation (NVAF), long 
term follow-up data are scarce to be certain whether the 
target INR level is maintained in warfarin-treated patients in 
Korea. The aim of this study was to evaluate how well INRs 
are maintained within the target range using a new index, 
INR stability (= 100 × number of INRs within target range/ 
total number of INR measurements) which we made, and to 
find out any correlation between thromboembolic events and 
INR stability. Materials and Methods: This study was an 
observational analysis of retrospectively collected data of 129 
patients with NVAF from April 2000 to December 2005 at 
a single tertiary hospital. All patients were registered at the 
anticoagulation service. Results: The median duration of 
follow up was 2.03 years (interquartile range 1.35 - 2.96). 
During the follow-up period, 60.9 ± 14.9% of the INR were 
within the target INR range. INR stability was not signi-
ficantly different between patients without and with stroke 
(61.2 ± 15.0% vs 53.3 ± 4.9%). Among the known factors 
affecting fluctuations of the INR value, the most frequent 
factor was noncompliance (41.8%). Conclusion: The present 
study showed that it was not enough to maintain INR values 
within the target range in warfarin-treated patients with 
NVAF even at a tertiary hospital. Noncompliance is an 
important problem which interferes with maintaining target 
INR range. 
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INTRODUCTION
Atrial fibrillation (AF) is an important arrhythmia 
because it is associated with an increased risk of 
systemic thromboembolism and stroke. The attribu-
table risk for stroke associated with AF increases 
steeply from 1.5% at age 50 - 59 years to 23.5% at 
age 80 - 89 years.
1
Five large randomized controlled primary pre-
vention trials and meta analysis study have shown 
that warfarin reduced the risk of stroke by about 
two thirds in people with non-valvular AF 
(NVAF), from overall 4.5% to 1.4% per year with 
little increase in frequency of major bleeding or 
intracranial hemorrhage.
2-7
Advancing age, prior stroke or transient is-
chemic attack, diabetes mellitus (DM), hyperten-
sion, dilated left atrium, and impaired function of 
the left ventricle are known risk factors for throm-
boembolic event.
8-12
Warfarin has been found to be effective for pri-
mary and secondary prevention of ischemic 
stroke, reducing the risk by 68% and the mor-
tality by 33%.
13 However, there are several pro-
blems in warfarin treatment which include narrow 
therapeutic range, much inter and intra individual 
variation, exorbitant price for antithrombotic effect, 
about a 4 day lag effect and essential monitoring.
The purposes of this observational study were 
to assess the degree of OAC in patients with 
NVAF, who were treated with warfarin, using 
new index which we made and evaluate the 
correlation between INR stability and thromboem-
bolic events.Jun Hyung Kim, et al. 84
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MATERIALS AND METHODS
Study population
This study included 129 patients with chronic 
NVAF who were treated with warfarin prior to 
conducting this study from April 2000 to Dec-
ember 2005. All patients were diagnosed as NVAF 
by an attending cardiologist at Samsung Medical 
Center.
NVAF was defined as an atrial fibrillation with-
out any stenotic valvular heart disease (VHD), 
ischemic heart disease and more than mild regur-
gitant VHD. 
We analyzed the following parameters for each 
patient: age, gender, dates of thromboembolic 
event and the INR values, dates of bleeding 
episode and INR values, and alcohol intake. In 
addition, known risk factors for stroke (past cere-
brovascular attack or transient ischemic attack, 
hypertension, congestive heart failure, and DM) 
were assessed, and left atrial diameter as well as 
left ventricular ejection fraction were estimated by 
transthoracic echocardiography. A CHADS2 score 
(congestive heart failure, hypertension, age > 75 
years, diabetes, and previous stroke or transient 
ischemic attack) which ranged from 0 to 6 was 
calculated for each patient. Patients were assigned 
points as follows: history of congestive heart 
failure = 1 point, history of hypertension = 1 point, 
age > 75 years = 1 point, history of diabetes 
mellitus = 1 point, and history of stroke including 
transient ischemic attack or systemic embolism =
2 points.
14
All patients were registered at the anticoagu-
lation service. Anticoagulation service was regarded 
as a mechanism to improve the provision of 
anticoagulation. The rationale for anticoagulation 
service is that the day-to-day details of anti-
coagulation management are delegated from busy 
physicians to an anticoagulation service manager 
(typically, a pharmacist, nurse or nurse practi-
tioner), who is responsible for dosing changes, 
scheduling patient education, and other aspects of 
anticoagulation management. When INR values 
are not within the therapeutic range, all possible 
reasons were recorded by the anticoagulation 
service. It was validated by an on-line database 
(Micromedex
Ⓡ).
When initiating warfarin therapy, warfarin 
should usually be initiated with a 4 mg dose (or 
2 to 3 mg in the very elderly). Adjusting a steady- 
state warfarin dose depends on the INR values 
measured and clinical factors. The total weekly 
dose should be changed by 10% to 20% for the 
most. The INR should be monitored frequently 
(e.g., at least once a week) immediately after 
initiation of warfarin. Subsequently, the interval 
between INR tests can be lengthened gradually 
(up to a maximum of 8 to 10 weeks) in patients 
with stable INR values.
INR stability
It was defined as a percentage of the value 
derived by dividing the number of INR within the 
target range by total number of INR measurement 
after first achievement of adequate INR range. In 
cases that subjects' INRs are out of the target 
range, repetitive INR measurements were per-
formed for relatively short time period. There-
fore, we excluded the INR values from measuring 
INR stability when the time period between any 
two consecutive measurements was less than 2 
weeks.
Subgroups
The subjects were divided into 2 subgroups to 
evaluate the relation between INR stability and 
clinical outcomes. One group was patients who 
suffered from stroke or thromboembolism, which 
the other group was patients without stroke or 
thromboembolism.
Statistical analysis
Statistical analysis was performed with SPSS 
software (ver. 13). Results are expressed as Fre-
quencies or percentages for categorical variables, 
and median (interquartile range) or mean ± SD for 
continuous variables. Comparisons were made by 
Student t-test or Mann-Whitney test for continu-
ous variables, and Chi-square test or Fisher's exact 
test was used for categorical variables. P  values 
less than 0.05 were considered statistically signifi-
cant.The Adequacy of Anticoagulation in AF 85
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Table 1. Demographics and Clinical Characteristics of 
Patients with Non-valvular Atrial Fibrillation 
Patients 
(n = 129)
%
Age (yrs)
< 60 47 36.4
60 - 69 37 28.7
70 - 79 33 25.6
80 - 89 12  9.3
Female 37 28.7
Stroke/TIA in FU period  4  3.1
Risk factors for stroke
Hypertension 75 58.1
CAD 12  9.3
DM 27 20.9
Heart failure 12  9.3
Prior stroke/TIA before enrollment  2  1.6
CHADS2 score
0 29 22.5
1 60 46.5
2 29 22.5
3  8  6.2
4  3  2.3
PPM insertion d/t sick 
  sinus syndrome
10  7.8
LA size (mm) 46.2 ± 6.4*
LV ejection fraction (%) 60 ± 9*
INR stability within the target 
  range (%)
 60.9 ± 14.9*
Weekly warfarin dose (mg) 27 (21 - 35)
†
FU period (y) 2.03 (1.35 - 2.96)
†
No of PT test per year 12.2 (9.3 - 17.6)
†
TIA, transient ischemic attack; FU, follow-up; CAD, coronary 
artery disease; DM, diabetes mellitus; LA, left atrium; LV, left 
ventricle; INR, international normalized ratio; PT, Prothrombin 
time; CHADS2 (congestive heart failure, hypertension, age > 
75 years, diabetes, and previous stroke or transient ischemic 
attack) score ranging from 0 to 6 was calculated for each 
patient; PPM, permanent pacemaker.
*Data presented are average ± standard deviation.
† Data presented are median (interquartile range).
RESULTS
Clinical characteristics of patients
This study included 129 patients, [92 men (71.3%) 
and 37 women (28.7%),] with NVAF, whose aver-
age age was 63.6 +/- 11.9 years (range 34 - 86 years). 
Most of them (36.4%) were less than 60 years old. 
The median duration of follow up was 2.03 years 
(interquartile range 1.35 - 2.96). Among the risk 
factors for stroke, hypertension was most com-
monly noted in 75 patients (58.1%), which DM in 
27 patients (20.9%). Mean time duration between 
2 consecutive measurements was 29.4 +/- 10.1 days. 
Coronary artery disease (CAD) and heart failure 
(HF) were noted in 12 patients (9.3%). Because our 
study had reviewd the date since April 2000, the 
indication of OAC did not always depend on 
CHADS11 score. Dilated LA size (≥ 50 mm) or 
age ≥ 75 years was the indication of OAC. Twenty 
nine patients (22.5%) had CHADS2 scores of 0. 
Prior stroke or transient ischemic attack (TIA) 
before enrollment was noted only in 2 patients 
(1.6%) (Table 1).
INR stability
During the follow-up period, the number of 
prothrombin time assessment per patient was 21 
± 10. The average value of INR stability was 60.9 
± 14.9% in all the patients. The INR values which 
were not within INR stability were divided into 
two groups. One group was INR values which 
were below the target range (31.2%), and the other 
group was INR values which were above the 
target range (9.1%) (Fig. 1).
Factors affecting INR stability
When the INR values were not within the target 
range, anticoagulation service asked and recorded 
the most appropriate reasons. It was regarded as 
noncompliance, when patients did not keep pre-
scription dosage and their INR values were out of 
the target range. When patients told anticoagu-
lation service that they drank an alcoholic bever-
age or ate something which interacts with warfarin, 
alcoholic beverage or something including func-
tional foods or dietary supplements were regarded 
as factors affecting INR stability. Drugs or herbal 
remedies were similarly regarded. After finding 
out the reason for fluctuations of INR values,Fig. 1. Distribution of INRs of all patients. 
INR stability was defined as a percentage 
of the value derived by dividing the 
numbers within the target INR range by 
the number of all prothrombin time as-
sessments after first achievement of ade-
quate INR range. Blue color expresses % 
duration within the target INR range, 
represented as 2 ≤ INR  ≤ 3. Red color 
expresses % duration below the target 
range represented as < 2 of INR. Green 
color expresses % duration above the target
range represented as > 3 of INR. INR, 
international normalized ratio. 
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Fig. 2. Factors affecting INR stability. Unknown occasion
52.8%, Noncompliance 19.8%, Food 13.2%, Drug 10.0%, 
Alcoholic beverage 3.1%, Herbal remedy 1.1%. INR, inter-
national normalized ratio.
Fig. 3. Comparison of INR stability between patients 
without stroke (n = 125) and those with stroke (n = 4). 
INR, international normalized ratio.
anticoagulation service spent time counselling 
patients and helped physicians to change dosing 
schedule. We did not find out the reasons affecting 
INR stability in significant number of cases (573 
occasions: 52.8%). Of all the known factors, non-
compliance was most commonly noted in 214 
occasions (19.8%), food in 143 occasions (13.2%), 
drug in 109 occasions (10.0%), alcoholic beverage 
in 34 occasions (3.1%) and herbal remedy in 12 
occasions (1.1%) (Fig. 2).
Comparison of INR stability between patients 
without and with stroke: Of 129 patients, only 4 
patients had stroke during the follow-up period. 
The mean INR stability was 53.3 ± 4.9% in patients 
with stroke, and 61.2 ± 15.0% in patients without 
stroke. It was not statistically different between 
the 2 subgroups (Fig. 3).
Correlation between weekly warfarin dose and 
age
The median value of weekly warfarin dose was 
27.0 (interquartile range 21.0 - 35). It seemed to be 
less than that of western population. It showed 
weakly inverse correlation with age (Fig. 4).The Adequacy of Anticoagulation in AF 87
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Fig. 4. Correlation between weekly warfarin dose and 
age.  p <0 . 0 0 1 .
Clinical events and complications during the follow- 
up period
Stroke was noted in 4 patients. Major bleeding 
complication was not noted, however, minor 
bleeding such as epistaxis was noted in 2 patients.
DISCUSSION
A significant proportion of patients with AF are 
not actually treated with warfarin despite its proven 
effectiveness in preventing stroke or systemic 
thromboembolism.
15-17 This suboptimal use of war-
farin may relate to unawareness among clinicians 
to guidelines and various risk stratification criteria 
with overestimation of bleeding risks. 
It is difficult to achieve INR values within the 
target range in a long-term follow-up, because of 
fluctuations of INR values, which can be attri-
buted to numerous factors including genetic factors, 
poor compliance with medication, drug to drug 
interactions, and change in diet.
18 Furthermore, it 
i s  h a r d  t o  k n o w  h o w  l o n g  t h e  t a r g e t  I N R  r a n g e  
is maintained during oral anticoagulation period. 
For example, even though a patient has a serial 
INR values in every month (for example, 1.8, 3.1, 
2.7,…), it is impossible to know an accurate period 
which was within the target INR range; Instead, 
only the INR numbers which are within the target 
range. Therefore, we prepared a new index, INR 
stability, to assess the degree of optimal OAC in 
patients with NVAF. 
Rosendaal et al.
19 proposed a method to deter-
mine the time interval between 2 INR measure-
ments, based on an assumption that actual differ-
ence in INR between any 2 consecutive measur-
ements is linear and the data are interpolated 
accordingly. Days in the first half of the interval 
are assigned to the first INR value and days in the 
second half to the second INR value. Even though 
it does not seem to be an adequate method to 
determine the interval between 2 INR measure-
ments and an annoying calculation to apply in 
clinical practice, there are several reports about 
the degree of optimal OAC in patients with AF 
using their method. The therapeutic range of INR 
was maintained how about 60% of the time in 
other studies.
16,20 In our study, the mean value of 
INR stability with new method was 60.9 ± 14.9% 
which was similar to previous reports.
An accurate time interval within the target INR 
range was not calculated by the new method as 
well, however our method was quicker and more 
easily applicable assessment in clinical practice 
than the method of Rosendaal et al.
19
The more the INR values are within the thera-
peutic range, the less either the ischemic stroke or 
bleeding complication occurs. However, our study 
did not show any significant differences in INR 
stability between patients with or without stroke. 
Our present study is a small population based 
study, and stroke incidence was very rare. More-
over, our study population included 89 patients 
(69%) with CHADS2 scores of 0 or 1. A large scale 
prospective study is needed to clarify the avail-
ability of INR stability in OAC.
The center where our study took place was a 
university teaching hospital. This center had 
anticoagulation service as well. It seemed to be a 
very useful system in controlling anticoagulation 
management, however, it exists rare by in Korea. 
Patients treated in other non-academic settings 
may not achieve this level. In other words, our 
study population might have a selection bias. 
There was an weakly inverse correlation between 
weekly warfarin dose and age. 
Factors which may lead to increased warfarin 
sensitivity are hypoalbuminemia, decreased die-
tary vitamin K intake, reduced absorption of Jun Hyung Kim, et al. 88
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vitamin K, and polypharmacy (producing drug- 
drug interactions that potentiate warfarin).
20 These 
factors may be mechanisms for increased sensiti-
vity to warfarin with aging, but further studies 
related with warfarin sensitivity are needed. Non-
compliance was a main problem to interfere with 
improving INR stability. We should focus on 
correcting it, until warfarin is replaced with a new 
drug which has no interaction with drug or food, 
adverse effects, and need of monitoring.
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